Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $1,134,900.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Joseph Lyon sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $113.49, for a total value of $1,134,900.00. Following the transaction, the insider owned 5,683 shares of the company’s stock, valued at approximately $644,963.67. This represents a 63.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Joseph Douglas Lyon also recently made the following trade(s):

• On Monday, August 3rd, Joseph Lyon sold 1,540 shares of Corcept Therapeutics stock. The stock was sold at an average price of $114.16, for a total value of $175,806.40.

Corcept Therapeutics Price Performance

CORT opened at $110.29 on Friday. The stock’s 50 day moving average price is $108.56 and its 200 day moving average price is $75.21. The stock has a market cap of $11.92 billion, a P/E ratio of 262.60 and a beta of 0.45. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $126.38.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The company had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm’s quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.86 EPS for the current year.

Wall Street Analyst Weigh In

CORT has been the topic of several research analyst reports. UBS Group set a $135.00 target price on shares of Corcept Therapeutics in a research note on Thursday, May 28th. HC Wainwright reaffirmed a “buy” rating and issued a $165.00 price target on shares of Corcept Therapeutics in a research note on Friday. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings lowered shares of Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 8th. Finally, Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $138.17.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Corcept Therapeutics in the 2nd quarter worth approximately $1,080,964,000. Parallel Advisors LLC boosted its holdings in Corcept Therapeutics by 2.5% during the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock worth $160,329,000 after buying an additional 96,763 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after buying an additional 734,646 shares in the last quarter. First Trust Advisors LP grew its position in Corcept Therapeutics by 213.5% in the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after buying an additional 1,480,059 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Corcept Therapeutics in the second quarter worth approximately $49,185,000. 93.61% of the stock is currently owned by institutional investors.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
• Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
• Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
• Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
• Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.